Extended [177Lu]Lu-PSMA RLT may improve the survival outcome of mCRPC patients with high-volume residual tumor after the completion of standard treatment with six cycles of [177Lu]Lu-PSMA-617. Here, FOLH1 is linked to neoplasm.